Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis
Farmacia Hospitalaria · 2025
DOI: 10.1016/j.farma.2024.04.023 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Clara Cortell-Fuster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital Universitario Doctor Peset, Valencia, Spain. Electronic address: cortell_cla@gva.es. Hauptthemen laut MEDLINE: Sirolimus, Angiofibroma, Tuberous Sclerosis, Facial Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
AIM: Topical rapamycin is the pharmacological treatment of choice for facial angiofibromas in rare tuberous sclerosis disease. A new, more advanced, and complex formula was developed in our pharmacy service: rapamycin 0.4% liposomal formulation, with better organoleptic characteristics and a more favorable release profile of the active ingredient. The purpose of this study is to evaluate the effectiveness and safety of liposomal topical rapamycin for the treatment of facial injuries in this rare disease. METHOD: This was an observational, prospective, and multicenter study. Effectiveness was evaluated mainly through facial angiofibroma severity index (FASI), investigator's global assessment (IGA) scores, and dermatology life quality index (DLQI) questionnaire. To assess the safety profile of rapamycin, adverse reactions were reported, and blood tests and blood rapamycin levels were performed during treatment. RESULTS: Eleven patients were included, of which 8/11 (73%) patients obtained successful treatment according to FASI and IGA scores after 24 weeks of treatment. Statistical analysis demonstrated a significant improvement (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Farmacia, Hospital Universitario Doctor Peset, Valencia, Spain. Electronic address: cortell_cla@gva.es.
- Servicio de Farmacia, Hospital Universitario Doctor Peset, Valencia, Spain.
- Servicio de Dermatología, Hospital Universitario Doctor Peset, Valencia, Spain.
- Servicio de Dermatología, Hospital Clínico Universitario, Valencia, Spain.
Zitieren
APA
Cortell-Fuster, C., Martínez-Gómez, M. A., Cercós-Lleti, A. C., Climente-Martí, M., Díaz-Corpas, T., Mateu-Puchades, A., & Revert-Fernández, Á. (2025). Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2024.04.023
Vancouver
Cortell-Fuster C, Martínez-Gómez MA, Cercós-Lleti AC, Climente-Martí M, Díaz-Corpas T, Mateu-Puchades A, et al. Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2024.04.023
BibTeX
@article{CortellFuster2025,
author = {Cortell-Fuster, Clara and Martínez-Gómez, María Amparo and Cercós-Lleti, Ana Cristina and Climente-Martí, Mónica and Díaz-Corpas, Tania and Mateu-Puchades, Almudena and Revert-Fernández, Ángeles},
title = {Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis},
journal = {Farmacia Hospitalaria},
year = {2025},
doi = {10.1016/j.farma.2024.04.023}
}
EUVIMED